Evidence map›Paper›PMID 22025886›Full record

ReviewJournal of magnetic resonance imaging : JMRI2011

Quantitative Assessment of Liver Fat with Magnetic Resonance Imaging and Spectroscopy.

Scott B Reeder, Irene Cruite, Gavin Hamilton, Claude B Sirlin

6 registry-linked trialsOpen access · bronzeAbstract readReview
In one paragraph

Review in Journal of magnetic resonance imaging : JMRI, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 6 registered trials, which are not on this map. Cited by 407 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
407citing papers in PubMed, 4 pooled it
24.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03590626 nacompletedstarted 2019, after this paper: background citation

Effect of Dulaglutide on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial

Ran2019Enrolled60Registered outcomes7Posted comparisons0ConditionsNon Alcoholic Fatty Liver Disease, Type2 Diabetes MellitusArmsDulaglutide
Open the trial in the graph
NCT05042505 nacompletedstarted 2022, after this paper: background citation

Effect of Dapagliflozin vs Sitagliptin on Liver Fat Accumulation and Body Composition in Patients With Diabetes Mellitus and Liver Transplantation: a Randomized Controlled Trial

Ran2022Enrolled100Registered outcomes5Posted comparisons0ConditionsDiabetes Mellitus, Liver Transplant; ComplicationsArmsDapagliflozin 10mg Tab, Sitagliptin 100mg
Open the trial in the graph
NCT06060392 narecruitingstarted 2023, after this paper: background citation

Effect of Oral Semaglutide on Liver Fat and Body Composition in Liver Transplant Recipients With Diabetes Mellitus: Sema-Lit

Ran2023Enrolled50Registered outcomes17Posted comparisons0ConditionsDiabete Mellitus, Liver Transplant; ComplicationsArmsSemaglutide Pill
Open the trial in the graph
NCT02686476 nacompletednot on this mapstarted 2016, after this paper: background citation

Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes: A 12-week Randomized Clinical Study

TypeinterventionalSponsorMedanta, The Medicity, IndiaRan2016 to 2017Enrolled100ConditionsNon Alcoholic Fatty Liver DiseaseArmsEmpagliflozin
NCT03528187 completednot on this mapstarted 2018, after this paper: background citation

To Investigate the Effect of Therapeutic Interventions Used in the Treatment of Obesity on Organ and Total Body Fat Measured Using MRI.

TypeobservationalSponsorUniversity College, LondonRan2018 to 2021Enrolled49ConditionsObesityArmsMRI, Written Consent
NCT06035874 narecruitingnot on this mapstarted 2023, after this paper: background citation

Effect of Bempedoic Acid on Liver Fat in Individuals With Nonalcoholic Fatty Liver Disease and Type 2 Diabetes: Randomized Controlled Trial

TypeinterventionalSponsorMedanta, The Medicity, IndiaRan2023 to 2025Enrolled100ConditionsType 2 Diabetes, Non Alcholic Fatty Liver DiseaseArmsBempedoic acid
3 · Its place in the literature

Who cites it

407 citing papers in PubMed, 4 syntheses or guidelines pooled it, 640 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

347 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Scott B ReederLiver Imaging Research Group, Departments of Radiology, Medical Physics, Biomedical Engineering and Medicine, University of Wisconsin, Madison, WI.
Irene Cruite
Gavin Hamilton
Claude B Sirlin
University of California, San Diego · US

Funding

Technical Validation of MRI Biomarkers of Liver FatR01DK088925 · NIDDK · UNIVERSITY OF WISCONSIN-MADISON · PI REEDER, SCOTT B., SIRLIN, CLAUDE B · 2010 to 2021
$7.1M
MR Imaging of Non-Alcoholic Fatty Liver DiseaseR01DK075128 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SIRLIN, CLAUDE B · 2006 to 2010
$2.4M
Technical Development of Quantitative Biomarkers of Fatty Liver Disease with MRIR01DK083380 · NIDDK · UNIVERSITY OF WISCONSIN-MADISON · PI REEDER, SCOTT B. · 2010 to 2013
$1.2M
Volumetric Perfusion MRI of Liver Tumors to Detect Early Response to ChemotherapyRC1EB010384 · NIBIB · UNIVERSITY OF WISCONSIN-MADISON · PI REEDER, SCOTT B. · 2009 to 2010
$973k
NIBIB NIH HHS RC1 EB010384NIDDK NIH HHS R01 DK075128NIDDK NIH HHS R01 DK083380NIDDK NIH HHS R01 DK088925
6 · The paper itself

Abstract

Hepatic steatosis is characterized by abnormal and excessive accumulation of lipids within hepatocytes. It is an important feature of diffuse liver disease, and the histological hallmark of non-alcoholic fatty liver disease (NAFLD). Other conditions associated with steatosis include alcoholic liver disease, viral hepatitis, HIV and genetic lipodystrophies, cystic fibrosis liver disease, and hepatotoxicity from various therapeutic agents. Liver biopsy, the current clinical gold standard for assessment of liver fat, is invasive and has sampling errors, and is not optimal for screening, monitoring, clinical decision making, or well-suited for many types of research studies. Non-invasive methods that accurately and objectively quantify liver fat are needed. Ultrasound (US) and computed tomography (CT) can be used to assess liver fat but have limited accuracy as well as other limitations. Magnetic resonance (MR) techniques can decompose the liver signal into its fat and water signal components and therefore assess liver fat more directly than CT or US. Most magnetic resonance (MR) techniques measure the signal fat-fraction (the fraction of the liver MR signal attributable to liver fat), which may be confounded by numerous technical and biological factors and may not reliably reflect fat content. By addressing the factors that confound the signal fat-fraction, advanced MR techniques measure the proton density fat-fraction (the fraction of the liver proton density attributable to liver fat), which is a fundamental tissue property and a direct measure of liver fat content. These advanced techniques show promise for accurate fat quantification and are likely to be commercially available soon.

Identifiers

PMID22025886
PMCPMC3177109
OpenAlexW2064403130

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.